ASKO THERAPEUTICS, INC.

Biotech · Private

Injectable biodegradable PLGA polymer implants for sustained monoclonal antibody delivery to hard-to-reach tissues

Grants
$700K
2 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Paradigm-changing, versatile, scalable and cost-effective technology for monthly injections of peptide drugs$350,027
Federal grantDepartment of Health and Human Services · Phase I · Novel injectable implants for long-term local controlled release of therapeutic monoclonal antibodies$350,027
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
3277VIROGENOMICS BIODEVELOPMENT, INC.——
3278ENZERNA BIOSCIENCES LLC——
3279Auratus Bio LLC——
3280ASKO THERAPEUTICS, INC.——
3281UNITED BIOTHERAPEUTICS LLC——
3282TARGETSITE THERAPEUTICS CORPORATION——
3283Seranova Bio, Inc.—$15M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.